Skip to main navigation Skip to search Skip to main content

Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer

  • Wei Yu
  • , Hongyan Chai
  • , Ying Li
  • , Haixia Zhao
  • , Xianfei Xie
  • , Hao Zheng
  • , Chenlong Wang
  • , Xue Wang
  • , Guifang Yang
  • , Xiaojun Cai
  • , John R. Falck
  • , Jing Yang*
  • *Corresponding author for this work
  • Univ Texas SW Med Ctr Dallas

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

Cytochrome P450 (CYP) 4Z1, a novel CYP4 family member, is over-expressed in human mammary carcinoma and associated with high-grade tumors and poor prognosis. However, the precise role of CYP4Z1 in tumor progression is unknown. Here, we demonstrate that CYP4Z1 overexpression promotes tumor angiogenesis and growth in breast cancer. Stable expression of CYP4Z1 in T47D and BT-474 human breast cancer cells significantly increased mRNA expression and production of vascular endothelial growth factor (VEGF)-A, and decreased mRNA levels and secretion of tissue inhibitor of metalloproteinase-2 (TIMP-2), without affecting cell proliferation and anchorage-independent cell growth in vitro. Notably, the conditioned medium from CYP4Z1-expressing cells enhanced proliferation, migration and tube formation of human umbilical vein endothelial cells, and promoted angiogenesis in the zebrafish embryo and chorioallantoic membrane of the chick embryo. In addition, there were lower levels of myristic acid and lauric acid, and higher contents of 20-hydroxyeicosatetraenoic acid (20-HETE) in CYP4Z1-expressing T47D cells compared with vector control. CYP4Z1 overexpression significantly increased tumor weight and microvessel density by 2.6-fold and 1.9-fold in human tumor xenograft models, respectively. Moreover, CYP4Z1 transfection increased the phosphorylation of ERK1/2 and PI3K/Akt, while PI3K or ERK inhibitors and siRNA silencing reversed CYP4Z1-mediated changes in VEGF-A and TIMP-2 expression. Conversely, HET0016, an inhibitor of the CYP4 family, potently inhibited the tumor-induced angiogenesis with associated changes in the intracellular levels of myristic acid, lauric acid and 20-HETE. Collectively, these data suggest that increased CYP4Z1 expression promotes tumor angiogenesis and growth in breast cancer partly via PI3K/Akt and ERK1/2 activation. (C) 2012 Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)73-83
Number of pages11
JournalToxicology and Applied Pharmacology
Volume264
Issue number1
DOIs
StatePublished - 1 Oct 2012

Funding

This work was supported by the National Natural Science Foundation of China [Grants 30973552 and 81173089 ] (to Jing Yang), the National Mega Project on Major Drug Development of China [Grants 2009ZX09301-014-1] (to Jing Yang) and the National Institutes of Health [Grants GM31278] (to John R. Falck).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cytochrome P450
  • Angiogenesis
  • VEGF-A
  • TIMP-2
  • Breast cancer

Indexed by

  • Scopus
  • SCIE

Fingerprint

Dive into the research topics of 'Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer'. Together they form a unique fingerprint.

Cite this